Dr Reddy’s Eyes Semaglutide Opportunity in India & Global Markets

Key Highlights • Plans to launch same Semaglutide product in India as offered in global markets • Confident in meeting domestic demand and expanding exports • In discussions with Canadian regulator for future launch • Management sees India GLP-1 market reaching ~$1 billion in next few years Why It Matters Semaglutide (GLP-1) is a high-growth segment driven by rising demand in diabetes and obesity treatment. Entry into this space can open significant revenue opportunities for pharma companies. Learning Outcome In pharmaceuticals, participation in high-growth therapy segments (like GLP-1) can drive long-term growth. Investors should track regulatory approvals, market size, and competitive positioning.